Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxurion NV Director's Dealing 2024

Sep 3, 2024

3987_mrq_2024-09-03_39a28fb9-4903-458d-832e-c6a9929ac2a1.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC

Leuven, BELGIË – 3 September 2024 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1 , de volgende transparantiekennisgeving heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 30 Augustus 2024 van Atlas Special Opportunities LLC waaruit blijkt dat het op 22 juli 2024 2.028.567.725 aandelen van de toen uitstaande 13.362.647.372 aandelen bezat en dus boven de drempel (15%) kwam door de aankoop van stemrechtverlenende effecten. Zie bijlage 1.

Oxurion ontving een transparantiekennisgeving op 30 Augustus 2024 van Atlas Special Opportunities LLC waaruit blijkt dat het op 31 juli 2024 1.937.193.391 aandelen van de toen uitstaande 13.362.647.372 aandelen bezat en dus onder de drempel (15%) kwam door de verkoop van stemrechtverlenende effecten. Zie bijlage 2.

Over Oxurion

Oxurion (Euronext Brussel: OXUR) houdt zich bezig met de ontwikkeling van de volgende generatie standaard oftalmologische therapieën voor de behandeling van netvliesaandoeningen. Oxurion is gevestigd in Leuven, België. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Voor meer informatie kunt u contact opnemen met:

Oxurion NV Pascal Ghoson Chief Executive Officer [email protected]

________

1. Artikel 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

ANNEX 1

FSMA FINANCIAL SERVICES AND
MARKETS AUTHORITY
Transparency notification
Form TR-1 BE
PART I
1) Status of the notification
Final
2) Issuer
Identification number 0881-620-924 Name OXURION
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name Address (for legal entities)
Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name Address (for legal entities)
B Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6 Part II
7) Date on which the threshold is crossed
22/07/2024 (DD/MMYYYY)
8) Threshold that is crossed (in %)
15
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
13,362,647,372
Please enter the denominator before filling in the data
10) Notified details
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights
% of voting rights
.
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
Atlas Special Opportunities LLC 941,611,204 2,028,567,725 15.18%
TOTAL 2.028.567.725 0 15.18% 0.00%
B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
+
TOTAL 0 0.00%
The totals will be updated once you have clicked on
P
TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 2,028,567,725 15.18%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.
12) In case of proxy voting for only one GM
(DD/MM/YYYY)
Holder will cease to hold / O voting rights as of
will hold again
13) Additional information
On 18 July 2024 (with settenent date on 22 July 2024), Allas Special Courin NY, as a result of which its stareboling incessed by 202,507,725 stares (s
15.18%, denominator = 13,362,647,372).
Done at New York
On
30/08/2024 (DD/MM/YYYY)
- DocuSigned by:
Name & capacity Patrick Vance, proxyholder Signature Patrick Varie

For security reasons, the unsigned form in xlsx format should be
transmitted to [email protected]. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be
transmitted.

ANNEX 2

FSMA
FINANCIAL SERVICES AND
MARKETS AUTHORITY
Transparency notification
Form TR-1 BE
PART I
1) Status of the notification
Final
2) Issuer
Name OXURION
ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name Address (for legal entities)
Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name Address (for legal entities)
B Please continue entering the information in part II concerning the
persons referred to in Sections 5 and 6
Part II
7) Date on which the threshold is crossed
31/07/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
15
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
13,362,647,372
Please enter the denominator before filling in the data
10) Notified details
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
Atlas Special Opportunities LLC 2,028,567,725 1,937,193,391 14.50%
TOTAL 1,937,193,391 o 14.50% 0.00%
B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
+
TOTAL 0 0.00%

The totals will be updated once you have clicked on

TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 1,937,193,391 14.50%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

(DD/MM/YYY)
Holder will cease to hold /
will hold again
voting rights as of

13) Additional information

On 20 July 2024 (with settlement date on 31 July 2024), Mas Special Opportunities LC sold 91,34 shares in Orunion its stransed to 1,937,99 shares (=
14.50%, denominator = 13,362,647,372).
Done at New York
On 30/08/2024 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder DOCUSTOMED Dy:
Patrick Vance
Signature
-- AEF6ADE 15-024BB.

For security reasons, the unsigned form in xlsx format should be
transmitted to trafin@fsmabe. You can do this manually
OR if you have MS Outlook at your disposal via the

In addition, a signed copy in PDE format should also be
transmitted.